Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
Hernández-Bernal F, Aguilar-Betancourt A, Aljovin V, Arias G, Valenzuela C, de Alejo KP, Hernández K, Oquendo O, Figueredo N, Figueroa N, Musacchio A, Véliz G, García E, Mollineda AD, Juvier AI, Trujillo J, Delahanty A, Ortega D, Cinza Z, González VL. Hernández-Bernal F, et al. Among authors: valenzuela c. Hum Vaccin. 2011 Oct;7(10):1026-36. doi: 10.4161/hv.7.10.15989. Epub 2011 Oct 1. Hum Vaccin. 2011. PMID: 21941089 Clinical Trial.
Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.
Gavilondo JV, Hernández-Bernal F, Ayala-Ávila M, de la Torre AV, de la Torre J, Morera-Díaz Y, Bequet-Romero M, Sánchez J, Valenzuela CM, Martín Y, Selman-Housein KH, Garabito A, Lazo OC; CENTAURO Group of Investigators. Gavilondo JV, et al. Among authors: valenzuela cm. Vaccine. 2014 Apr 17;32(19):2241-50. doi: 10.1016/j.vaccine.2013.11.102. Epub 2014 Feb 11. Vaccine. 2014. PMID: 24530151 Clinical Trial.
HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.
Amador-Cañizares Y, Martínez-Donato G, Alvarez-Lajonchere L, Vasallo C, Dausá M, Aguilar-Noriega D, Valenzuela C, Raíces I, Dubuisson J, Wychowski C, Cinza-Estévez Z, Castellanos M, Núñez M, Armas A, González Y, Revé I, Guerra I, Pérez Aguiar A, Dueñas-Carrera S. Amador-Cañizares Y, et al. Among authors: valenzuela c. World J Gastroenterol. 2014 Jan 7;20(1):148-62. doi: 10.3748/wjg.v20.i1.148. World J Gastroenterol. 2014. PMID: 24415868 Free PMC article. Clinical Trial.
Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.
Sarduy MR, García I, Coca MA, Perera A, Torres LA, Valenzuela CM, Baladrón I, Solares M, Reyes V, Hernández I, Perera Y, Martínez YM, Molina L, González YM, Ancízar JA, Prats A, González L, Casacó CA, Acevedo BE, López-Saura PA, Alonso DF, Gómez R, Perea-Rodríguez SE; CERVIFARM-300-II Study Group. Sarduy MR, et al. Among authors: valenzuela cm. Br J Cancer. 2015 May 12;112(10):1636-43. doi: 10.1038/bjc.2015.137. Epub 2015 Apr 16. Br J Cancer. 2015. PMID: 25880012 Free PMC article. Clinical Trial.
Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P. Solares AM, et al. Among authors: valenzuela c. BMC Cancer. 2009 May 13;9:146. doi: 10.1186/1471-2407-9-146. BMC Cancer. 2009. PMID: 19439079 Free PMC article. Clinical Trial.
Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.
Solares AM, Baladron I, Ramos T, Valenzuela C, Borbon Z, Fanjull S, Gonzalez L, Castillo D, Esmir J, Granadillo M, Batte A, Cintado A, Ale M, Fernandez de Cossio ME, Ferrer A, Torrens I, Lopez-Saura P. Solares AM, et al. Among authors: valenzuela c. ISRN Obstet Gynecol. 2011;2011:292951. doi: 10.5402/2011/292951. Epub 2011 Mar 24. ISRN Obstet Gynecol. 2011. PMID: 21748025 Free PMC article.
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Among authors: valenzuela c. Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25. Mol Cell Biochem. 2008. PMID: 18575815 Clinical Trial.
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Among authors: valenzuela c. Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7. Mol Cell Biochem. 2011. PMID: 21735096 Clinical Trial.
Heberprot-P: a novel product for treating advanced diabetic foot ulcer.
Berlanga J, Fernández JI, López E, López PA, del Río A, Valenzuela C, Baldomero J, Muzio V, Raíces M, Silva R, Acevedo BE, Herrera L. Berlanga J, et al. Among authors: valenzuela c. MEDICC Rev. 2013 Jan;15(1):11-5. doi: 10.37757/MR2013V15.N1.4. MEDICC Rev. 2013. PMID: 23396236 Free article.
815 results